CoChat

In Vivo Biosafety Model to Assess the Risk of Adverse Events From Retroviral and Lentiviral Vectors

Open access
Bauer, Gerhard, Dao, Mo A, Case, Scott S, Meyerrose, Todd, Wirthlin, Louisa, Zhou, Ping, Wang, Xiuli, Herrbrich, Phillip, Arevalo, Jesusa, Csik, Susie, Skelton, Dianne C, Walker, Jon, Pepper, Karen, Kohn, Donald B, Nolta, Jan A · 2008 · Molecular Therapy
Cited by 69

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Serious adverse events in some human gene therapy clinical trials have raised safety concerns when retroviral or lentiviral vectors are used for gene transfer. We evaluated the potential for generating replication-competent retrovirus (RCR) and assessed the risk of occurrence of adverse events in an in vivo system. Human hematopoietic stem and progenitor cells (HSCs) and mesenchymal stem cells (MSCs) transduced with two different Moloney murine leukemia virus (MoMuLV)-based vectors were cotransplanted into a total of 481 immune-deficient mice (that are unable to reject cells that become transformed), and the animals were monitored for 18 months. Animals with any signs of illness were immediately killed, autopsied, and subjected to a range of biosafety studies. There was no detectable evidence of insertional mutagenesis leading to human leukemias or solid tumors in the 18 months during which the animals were studied. In 117 serum samples analyzed by vector rescue assay there was no detectable RCR. An additional 149 mice received HSCs transduced with lentiviral vectors, and were followed for 2-6 months. No vector-associated adverse events were observed, and none of the mice had detectable human immunodeficiency virus (HIV) p24 antigen in their sera. Our in vivo system, therefore, helps to provide an assessment of the risks involved when retroviral or lentiviral vectors are considered for use in clinical gene therapy applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2008.93

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 69

Metadata

Authors
Bauer, G., Dao, M. A., Case, S. S., Meyerrose, T., Wirthlin, L., Zhou, P., Wang, X., Herrbrich, P., Arevalo, J., Csik, S., Skelton, D. C., Walker, J., Pepper, K., Kohn, D. B., & Nolta, J. A.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2008-07
Volume
16
Issue
7
Pages
1308-1315
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2131115331
Cited by
69
References
3
FWCI
4.57
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In Vivo Biosafety Model to Assess the Risk of Adverse Events From Retroviral and Lentiviral Vectors. https://app.cochat.ai/papers/10.1038/mt.2008.93
The paper
Bauer, G., Dao, M. A., Case, S. S., Meyerrose, T., Wirthlin, L., Zhou, P., Wang, X., Herrbrich, P., Arevalo, J., Csik, S., Skelton, D. C., Walker, J., Pepper, K., Kohn, D. B., & Nolta, J. A. (2008). In Vivo Biosafety Model to Assess the Risk of Adverse Events From Retroviral and Lentiviral Vectors. Molecular Therapy. https://doi.org/10.1038/mt.2008.93

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.